The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2016 | Development and application of virus-specific T cells
Ann Leen, PhD, from Baylor College of Medicine, Houston, TX, US, provides an overview of virus-specific T cells from how they were first developed to the advances that have been made to date. Dr Leen describes how virus-specific T cell were first developed to target Epstein-Barr virus (EBV) and cytomegalovirus (CMV), which are problematic in immunocompromised individuals. She further explains why virus-specific T cells are important for patients who are immunocompromised and how the spectrum of viruses that can be targeted, has been expanded to include adenoviruses, the BK virus, and human herpes virus 6. According to Dr Leen, one of the main new developments in this area has been around how the cells are administered as this has broadened the applicability of this therapy.
Recorded at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.
